Skip to main content
SpringerLink
Log in

Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study

  • Chapter
Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 353))

Abstract

The concept of using monoclonal antibodies (MAbs) to localize and treat human tumors has become a clinical reality over the last few years. Antibodies have been used to modulate the host immune system to activate tumoricidal effector mechanisms and are being used as targeting vehicles for delivery of exogenous cytotoxic molecules such as radioisotopes, chemicals and biologicals. Their ability to selectively target tumor cells also makes them attractive for radioimmunoimaging and for assessing tumor response to therapy1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blakely DC. Drug targeting with monoclonal antibodies-A review. Acta Oncol 1992; 31: 91–97.

    Article  Google Scholar 

  2. Kohler S, Milstein G. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497.

    Article  PubMed  CAS  Google Scholar 

  3. Tjandra JJ, Ramadi L, McKenzie IFC. Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 1990; 68: 367–376.

    Article  PubMed  Google Scholar 

  4. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530–1535.

    PubMed  CAS  Google Scholar 

  5. Dykewicz MS, Cranberg JA, Patterson R, Rosen ST, Shaughnessy MA, Zimmer AM. Human IgE, IgG and IgA antibody responses to T101, a murine monoclonal antibody against human lymphocytes: implications for pathogenesis, risk and avoidance of adverse immunologic reactions. Int Arch Allergy Appl Immunol 1990; 92: 131–137.

    Article  PubMed  CAS  Google Scholar 

  6. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879–885.

    PubMed  CAS  Google Scholar 

  7. Van Kroonenburgh MJPG, Pauwels EKJ. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 1988; 9: 919–930.

    Article  PubMed  Google Scholar 

  8. Jailer GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. Monoclonal Antibody Therapy: Anti-idiotypic and non-idiotypic antibodies to OKT3 arising depsite intense immunosuppression. Transplantation 1986; 41: 572–578.

    Article  Google Scholar 

  9. Thistlethwaite JR, Jr., Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 1984; 38: 695–701.

    Article  PubMed  Google Scholar 

  10. Sears Hf, Bagli DJ, Herlyn D. Human immune response to monoclonal antibody administration is dose-dependent. Arch Surg 1987; 122: 1384–1388.

    Article  PubMed  CAS  Google Scholar 

  11. Sears Hf, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Modifiers 1984; 3: 138–150.

    CAS  Google Scholar 

  12. Ledermann JA, Begent RHJ, Bagshawe KD. Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumor antibody in rabbits. Br J Cancer 1988; 58: 562–566.

    Article  PubMed  CAS  Google Scholar 

  13. Ledermann J A, Begent RHJ, Bagshawe KD, et al. Repeated antitumor antibody therapy in man with suppression of the host response by Cyclosporin A. Br J Cancer 1988; 58: 654–657.

    Article  PubMed  CAS  Google Scholar 

  14. Engemann R, Gassel HJ, Lafrenz E, Stoffregen C, Thiede A. Transplantation tolerance after short-term administration of 15-Deoxyspergualin in orthotopic rat liver transplantation. Transplant Proc 1987; XIX: 4241–4243.

    Google Scholar 

  15. Amemiya H, Suzuki S, Manabe H, et al. 15-Deoxyspergualin in an immunosuppressive agent in dogs. Transplant Proc 1988; XX: 229–232.

    Google Scholar 

  16. Kaufman DB, Field MJ, Gruber SA, et al. Extended functional survival of murine islet allografts with 15-deoxyspergualin. Transplant Proc 1992; 24: 1045–1047.

    PubMed  CAS  Google Scholar 

  17. Collier DStJ, Caine R, Thiru S, Kohno H, Levickis J. 15-Deoxyspergualin in experimental dog renal allografts. Transplant Proc 1988; XX: 240–241.

    Google Scholar 

  18. Amemiya H, Suzuki S, Ota K, et al. A novel rescue drug, 15-deoxyspergualin: first clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990; 49: 337–343.

    Article  PubMed  CAS  Google Scholar 

  19. Schorlemmer HU, Bartlett RR, Schleyerbach R, Dickneite G, Seller FR. Immunosuppressive therapy of experimental autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus by 15-deoxyspergualin. Int J Immunotherapy 1989; 1: 9–20.

    Google Scholar 

  20. Schorlemmer HU, Seller FR. Therapeutic effects of 15-deoxyspergualin in acute and chronic relapsing experimental allergic encephalomyelitis (EAE) as models for multiple sclerosis (MS). Drugs Exptl Clin Res 1991; XVII: 461–469.

    Google Scholar 

  21. Schorlemmer HU, Bartlett RR, Seller FR. 15-Deoxyspergualin (15-DSG) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice. Agents and Actions 1991; 34: 151–155.

    Article  PubMed  CAS  Google Scholar 

  22. Kerr PG, Atkins C. Deoxyspergualin inhibits cytotoxic T lymphocytes but not NK or LAK cells. Immunol Cell Biol 1991; 69: 177–183.

    Article  PubMed  CAS  Google Scholar 

  23. Thomas F, Matthews C, Pittman K, Thomas J. 15-Deoxyspergualin produces inhibition of lymphokine-activated killer cell activity. Transplant Proc 1992; 24: 712–713.

    PubMed  CAS  Google Scholar 

  24. Fujii H, Takada T, Nemo K, et al. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot 1990; 43: 213–219.

    Article  PubMed  CAS  Google Scholar 

  25. Tepper M, Petty B, Bursuker I, Pasternak R, Schacter BZ. Inhibition of antibody production by immunosuppressive agent, deoxyspergualin. Transplant Proc 1991; 23: 328–331.

    PubMed  CAS  Google Scholar 

  26. Nemoto K, Hayashi M, Abe F. Immunosuppressive activities of 15-deoxyspergualin in animals. J Antibiot 1987; 40: 561–562.

    Article  Google Scholar 

  27. Pai LH, Fitzgerald DJ, Tepper M, Schacter B, Spitainy G, Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990; 50: 7750–7753.

    PubMed  CAS  Google Scholar 

  28. Hellstrom I, Garrigues U, Lavie E,et.al.. Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Res 1988; 48: 624–627.

    PubMed  CAS  Google Scholar 

  29. Goodman GE, Hellstrom I, Brodzinsky L, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J ClinOncol 1990; 8: 1083–1092.

    CAS  Google Scholar 

  30. Ziegler LD, Palazzolo P, Cunningham J, et al. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 1992; 10: 1470–1478.

    PubMed  CAS  Google Scholar 

  31. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4224.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

    Kapil Dhingra, Daniel Booser, Aman Buzdar, Martin Raber, Lia Gutierrez & Gabriel Hortobagyi

  2. Departments of Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

    Herbert Fritsche

  3. Departments of Clinical Immunology and Biological Therapy, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

    James L. Murray

  4. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA

    Albert F. LoBuglio & M. B. Khazaeli

  5. Bristol-Myers Squibb Company, Wallingford, Connecticut, 06492, USA

    Susan Kelley, Mark Tepper & Douglas Greene

Authors
  1. Kapil Dhingra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Booser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aman Buzdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Raber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lia Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriel Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Herbert Fritsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James L. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Albert F. LoBuglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. B. Khazaeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Susan Kelley
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mark Tepper
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Douglas Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Research Fund of Contra Costa, Walnut Creek, California, USA

    Roberto L. Ceriani

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dhingra, K. et al. (1994). Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2443-4_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6038-4

  • Online ISBN: 978-1-4615-2443-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation